Trials / Completed
CompletedNCT02358889
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Iconic Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | hI-con1 | Intravitreal injection of hI-con1 0.3 mg |
| BIOLOGICAL | ranibizumab | Intravitreal injection of ranibizumab 0.5 mg |
| OTHER | Sham injection | No injection is given, a needleless syringe is used to mimic an injection. |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2015-02-09
- Last updated
- 2020-09-24
- Results posted
- 2020-09-24
Locations
48 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02358889. Inclusion in this directory is not an endorsement.